Related Experiment Video
Updated: Sep 8, 2025
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
High miR-200a-3p expression has high diagnostic values for hypertensive disorders complicating pregnancy and predicts
Xin He1, Danni Ding2
1Department of Obstetrics, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, 61 Jiefang West Road, Changsha, 410005, Hunan, China.
Insights
Elevated microRNA-200a-3p (miR-200a-3p) in serum aids in diagnosing hypertensive disorders complicating pregnancy (HDCP) and predicting adverse outcomes. Higher miR-200a-3p levels correlate with disease severity and poorer maternal-fetal health.
Area of Science:
- Biochemistry
- Genetics
- Obstetrics
Background:
- Hypertensive disorders complicating pregnancy (HDCP) encompass diverse conditions.
- microRNA (miR)-200a-3p has emerged as a potential biomarker in HDCP diagnosis.
Purpose of the Study:
- To investigate the diagnostic and prognostic value of serum miR-200a-3p in HDCP.
- To explore the correlation between miR-200a-3p expression and clinical indicators, as well as maternal and fetal outcomes.
Main Methods:
- Serum miR-200a-3p expression was measured in 126 HDCP patients (gestational hypertension, mild preeclampsia, severe preeclampsia) and 50 controls.
- Diagnostic efficacy for HDCP and its subtypes was evaluated.
- Correlations with clinical indexes and follow-up of maternal/fetal outcomes were analyzed.
Main Results:
- Serum miR-200a-3p was significantly upregulated in HDCP patients.
- miR-200a-3p demonstrated high sensitivity (87.3%) and specificity (96.0%) for HDCP diagnosis.
- Expression levels increased with disease severity and correlated with adverse pregnancy outcomes.
Conclusions:
- Serum miR-200a-3p is a valuable biomarker for diagnosing HDCP and assessing its severity.
- Elevated miR-200a-3p expression is linked to an increased incidence of adverse pregnancy outcomes.
Background:
Hypertensive disorders complicating pregnancy (HDCP) are various heterogeneous conditions. microRNA (miR)-200a-3p is involved in HDCP diagnosis. This study explored the effects of miR-200a-3p on HDCP patients.
Methods:
A total of 126 singleton HDCP patients including 50 cases of gestation hypertension (GH), 42 cases of mild preeclampsia (MP) and 34 cases of severe preeclampsia (SP), were enrolled as study subjects, and 50 normal pregnant women were selected as the control. Serum miR-200a-3p expression was detected and its efficacy in HDCP diagnosis and grading was evaluated. GH, MP and SP patients were allocated to high/low miR-200a-3p expression groups. The correlation between miR-200a-3p expression and general clinical indexes was analyzed. HDCP patients were allocated to high/low miR-200a-3p expression group and maternal and fetal outcomes were followed up. Effects of miR-200a-3p expression on adverse pregnancy outcome incidence were analyzed.
Results:
miR-200a-3p expression in the serum of HDCP patients was upregulated. The sensitivity and specificity of serum miR-200a-3p level > 1.201 were 87.3% and 96.0%, respectively. Serum miR-200a-3p level in GH, MP and SP patients was increased with the aggravation of the disease. The cut-off value and area under the curve (AUC) of miR-200a-3p for GH, MP and SP diagnosis were 1.145 and 0.9094 (82.0% sensitivity and 88.0% specificity), 1.541 and 0.8126 (73.8% sensitivity and 76.0% specificity), and 1.866 and 0.7367 (64.7% sensitivity and 76.2% specificity), respectively. Serum miR-200a-3p level was correlated with general clinical indexes, fetal birth weight, systolic to diastolic ratio, and fetal growth restriction incidence. High serum miR-200a-3p expression in HDCP patients was associated with increased adverse pregnancy outcomes.
Conclusion:
High miR-200a-3p expression could help to diagnose HDCP, judge severity and was associated with increased adverse pregnancy outcomes.
